Warning: The NCBI web site requires JavaScript to function. more...
Therapeutic targets in systemic sclerosis.
Denton CP.
Arthritis Res Ther. 2007;9 Suppl 2:S6. Review.
Related citations
Targeted therapy comes of age in scleroderma.
Denton CP, Black CM.
Trends Immunol. 2005 Nov;26(11):596-602. Epub 2005 Sep 15. Review.
Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP, Black CM, Abraham DJ.
Nat Clin Pract Rheumatol. 2006 Mar;2(3):134-44. Review.
Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
Shiwen X, Leask A, Abraham DJ, Fonseca C.
Eur J Clin Invest. 2009 Jun;39 Suppl 2:19-26. Review. Erratum in: Eur J Clin Invest. 2009 Jul;39(7):630.
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P, Coghlan G.
Drugs. 2008;68(12):1635-45. Review.
Management of systemic sclerosis: the art and science.
Stone JH, Wigley FM.
Semin Cutan Med Surg. 1998 Mar;17(1):55-64. Review.
New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
Zandman-Goddard G, Tweezer-Zaks N, Shoenfeld Y.
Clin Dev Immunol. 2005 Sep;12(3):165-73. Review.
Skin disease: a cardinal feature of systemic sclerosis.
Krieg T, Takehara K.
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii14-8. Review.
The immunobiology of systemic sclerosis.
Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME.
Semin Arthritis Rheum. 2008 Oct;38(2):132-60. Epub 2008 Jan 25. Review.
Bosentan in systemic sclerosis.
Heresi GA, Minai OA.
Drugs Today (Barc). 2008 Jun;44(6):415-28. Review.
Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.
Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G.
Ann Rheum Dis. 2008 Aug;67(8):1121-6. Epub 2007 Nov 20.
Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
Jain M, Varga J.
Expert Opin Pharmacother. 2006 Aug;7(11):1487-501. Review.
Future targets in the management of systemic sclerosis.
Tyndall A, Matucci-Cerinic M, Müller-Ladner U.
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii49-53. Review.
Therapeutic challenges for systemic sclerosis: facts and future targets.
Cerinic Matucci M, Del Rosso A, Federico P, Livi R, Fiori G, Bartoli F, Blagojevic J, Tempestini A, Pignone A.
Ann N Y Acad Sci. 2007 Sep;1110:448-54.
Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1.
Richard V, Solans V, Favre J, Henry JP, Lallemand F, Thuillez C, Marie I.
Fundam Clin Pharmacol. 2008 Dec;22(6):649-55.
How does endothelial cell injury start? The role of endothelin in systemic sclerosis.
Abraham D, Distler O.
Arthritis Res Ther. 2007;9 Suppl 2:S2. Review.
New pathogenic and therapeutic concepts in systemic sclerosis.
Hügle T, Huigens CA, van Laar JM.
Arzneimittelforschung. 2009;59(12):615-24. Review.
Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M, Varga J.
Curr Opin Rheumatol. 2007 Nov;19(6):568-73. Review.
Endothelin and scleroderma lung disease.
Silver RM.
Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v25-6. Review.
Cytokine directed therapy in scleroderma: rationale, current status, and the future.
Simms RW, Korn JH.
Curr Opin Rheumatol. 2002 Nov;14(6):717-22. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on